AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16996004 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP and BPBM (test group, n = 9)
Number of subjects: 10
Study 16996004 — intervention group
Group type: COMPARATOR
Intervention: BPBM alone (control group, n = 8)
Number of subjects: 10
Study 12687824 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD+ mode
Number of subjects: 100
Study 12687824 — intervention group
Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 100
Study 12687824 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing
Number of subjects: 100
Study 12557136 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 257
Study 12557136 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily)
Number of subjects: 257
Study 12557136 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 257
Study 12557136 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 257
Study 10682150 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zanamivir powder for inhalation
Number of subjects: 116
Study 10682150 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zanamivir powder for inhalation plus 6.4 mg zanamivir nasal spray
Number of subjects: 116
Study 10682150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 8922541 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 183
Study 8922541 — intervention group
Group type: COMPARATOR
Intervention: BMI of 30 kg/m2 or more
Number of subjects: 183
Study 8922541 — intervention group
Group type: COMPARATOR
Intervention: Increase in BMI during follow-up
Number of subjects: 183
Study 8922541 — intervention group
Group type: COMPARATOR
Intervention: Fasting insulin levels of 8.1-12.9 mU/1
Number of subjects: 183
Study 8922541 — intervention group
Group type: COMPARATOR
Intervention: Fasting insulin levels of 13.0 mU/1 or more
Number of subjects: 183
Study 8922541 — intervention group
Group type: COMPARATOR
Intervention: Degree of glucose intolerance and diagnosis of hypertension
Number of subjects: 183
Study 1991783 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed intramedullary nailing
Number of subjects: 0
Study 1991783 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 6340158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (meglumine iothalamate)
Number of subjects: 30
Study 6340158 — intervention group
Group type: COMPARATOR
Intervention: Conray (meglumine ioxaglate)
Number of subjects: 30
Study 2948752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (300 mmol per day)
Number of subjects: 6
Study 2948752 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (40 mmol per day)
Number of subjects: 6
Study 31994262 — intervention group
Group type: EXPERIMENTAL
Intervention: Designed program based on game situations (Experimental Group - EG)
Number of subjects: 28
Study 31994262 — intervention group
Group type: COMPARATOR
Intervention: Adapted Physical Education (APE) program (Control Group - CG)
Number of subjects: 28
Study 29332135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential GnRHa treatment
Number of subjects: 216
Study 29332135 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous GnRHa treatment
Number of subjects: 216
Study 29332135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 216
Study 27521254 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake ≥60 g/d
Number of subjects: 77
Study 26517595 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM training for physicians (12 hours of training including decision aids)
Number of subjects: 160
Study 26517595 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM training for physicians
Number of subjects: 160
Study 23936756 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 546)
Number of subjects: 2331
Study 23936756 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 507)
Number of subjects: 2331
Study 23936756 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331
Study 23936756 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD presence
Number of subjects: 2331
Study 21134505 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg daily for 2 days followed by 800 mcg vaginal misoprostol
Number of subjects: 40
Study 21134505 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg combined with 200 mg mifepristone
Number of subjects: 40
Study 18284434 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg daily
Number of subjects: 515
Study 18284434 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg daily
Number of subjects: 515
Study 18284434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study 16502177 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 116
Study 16502177 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 116
Study 12772141 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior perineal block (PPB) with 0.75% ropivacaine, 40 mL
Number of subjects: 0
Study 12772141 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PPB)
Number of subjects: 0
Study 11253444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) during hospitalization
Number of subjects: 580
Study 11253444 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use among patients doing anything to help quit smoking at admission
Number of subjects: 580
Study 11253444 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use among patients seriously planning to quit smoking within 30 days
Number of subjects: 580
Study 11253444 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use among nicotine dependent patients
Number of subjects: 580
Study 11253444 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT use among patients offered prescription by a physician
Number of subjects: 580
Study 9314128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg orally)
Number of subjects: 18
Study 8380606 — intervention group
Group type: EXPERIMENTAL
Intervention: hBNP (2.0 pmol/kg.min)
Number of subjects: 6
Study 8380606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3490559 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine therapy
Number of subjects: 25
Study 3490559 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation during thyroxine therapy
Number of subjects: 25
Study 3490559 — intervention group
Group type: COMPARATOR
Intervention: Before treatment
Number of subjects: 25
Study 29729429 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin administered intravenously 30 minutes before incision and every 8 hours for 24 hours post-operation
Number of subjects: 30
Study 29729429 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline administered
Number of subjects: 30
Study 27484001 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training prior to the step-reduction intervention (PT-group)
Number of subjects: 30
Study 27484001 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based 'exercise snacking' three times per day during the step-reduction intervention (ES-group)
Number of subjects: 30
Study 27484001 — intervention group
Group type: COMPARATOR
Intervention: Step-reduction intervention only (Control group)
Number of subjects: 30
Study 25394805 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week recurrent fall prevention program (strength training, balance training, patient education)
Number of subjects: 62
Study 25394805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 62
Study 22345677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 31
Study 22345677 — intervention group
Group type: COMPARATOR
Intervention: Education programme
Number of subjects: 31
Study 20202516 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg)
Number of subjects: 20
Study 20202516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20202516 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg orally twice daily for 5 days) followed by Rosuvastatin (40 mg)
Number of subjects: 20
Study 20202516 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (200 mg orally twice daily for 5 days) followed by Placebo
Number of subjects: 20
Study 18209256 — intervention group
Group type: EXPERIMENTAL
Intervention: Move and learn curriculum
Number of subjects: 0
Study 18209256 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum
Number of subjects: 0
Study 16314196 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ SPECT
Number of subjects: 31
Study 16314196 — intervention group
Group type: EXPERIMENTAL
Intervention: LDDE
Number of subjects: 31
Study 16314196 — intervention group
Group type: COMPARATOR
Intervention: Placebo SPECT
Number of subjects: 31
Study 16314196 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 31
Study 16314196 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 31
Study 16314196 — intervention group
Group type: COMPARATOR
Intervention: No viability
Number of subjects: 31
Study 12846468 — intervention group
Group type: EXPERIMENTAL
Intervention: Asset-tracking system using combined radiofrequency and infrared signals
Number of subjects: 0
Study 12846468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no asset-tracking system)
Number of subjects: 0
Study 11212905 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC 750 mg/m2 IV day 1 every 28 days (Arm A)
Number of subjects: 39
Study 11212905 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC 200 mg/m2 IV days 1-5 every 28 days (Arm B)
Number of subjects: 39
Study 9344624 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ppm 13C2-BE vapor for 2 hours
Number of subjects: 6
Study 9344624 — intervention group
Group type: COMPARATOR
Intervention: Blood sampling techniques (finger prick vs catheter)
Number of subjects: 6
Study 9344624 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine collection for 24 hours
Number of subjects: 6
Study 9344624 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPK modeling of worst-case exposure scenarios
Number of subjects: 6
Study 9344624 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated exercise with whole-body exposures
Number of subjects: 6
Study 9344624 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic exposures of only the arms and head
Number of subjects: 6
Study 8472719 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg twice daily
Number of subjects: 24
Study 8472719 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg twice daily
Number of subjects: 24
Study 8472719 — intervention group
Group type: COMPARATOR
Intervention: atenolol monotherapy
Number of subjects: 24
Study 2986275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 68
Study 2986275 — intervention group
Group type: COMPARATOR
Intervention: Alginate/antacid
Number of subjects: 68
Study 31577035 — intervention group
Group type: EXPERIMENTAL
Intervention: Selepressin (1.7, 2.5, and 3.5 ng/kg/min; n=585)
Number of subjects: 868
Study 31577035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=283)
Number of subjects: 868
Study 31577035 — intervention group
Group type: EXPERIMENTAL
Intervention: Selepressin (1.7, 2.5, and 3.5 ng/kg/min)
Number of subjects: 868
Study 31577035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study 28412178 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening and decolonization for MRSA
Number of subjects: 0
Study 28412178 — intervention group
Group type: COMPARATOR
Intervention: Standard precautions
Number of subjects: 0
Study 25547064 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vancomycin
Number of subjects: 44
Study 25547064 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose vancomycin
Number of subjects: 44
Study 23953789 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 45 patients)
Number of subjects: 91
Study 23953789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n = 46 patients)
Number of subjects: 91
Study 23953789 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion in PROP group
Number of subjects: 91
Study 23953789 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion in DEX group
Number of subjects: 91
Study 22093213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction (phlebotomy)
Number of subjects: 1277
Study 22093213 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1277
Study 19501292 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 33
Study 19501292 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 33
Study 17209786 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal intervention (scaling and root planing, sonic toothbrush)
Number of subjects: 67
Study 17209786 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal intervention
Number of subjects: 67
Study 17209786 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy without periodontal treatment
Number of subjects: 67
Study 12631411 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐cyclodextrin‐artemisinin complex (150 mg artemisinin)
Number of subjects: 100
Study 12631411 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin 250 (250 mg artemisinin)
Number of subjects: 100
Study 10869918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion at a rate of 1 to 2.5 mcg/kg/min to maintain moderate controlled hypotension
Number of subjects: 32
Study 10869918 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia supplemented with nitrous oxide (N2O)
Number of subjects: 32
Study 9375480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients
Number of subjects: 56
Study 9375480 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 56
Study 1589726 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 61
Study 1589726 — intervention group
Group type: COMPARATOR
Intervention: No treatment with antibiotics (Control)
Number of subjects: 61
Study 3840029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g sucralfate
Number of subjects: 0
Study 3840029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30226889 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with metabolic risk factors
Number of subjects: 215
Study 30226889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 215
Study 26969955 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 60
Study 26969955 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic double-row repair alone
Number of subjects: 60
Study 23161345 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP followed by diode laser (test)
Number of subjects: 30
Study 23161345 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (control)
Number of subjects: 30
Study 22985137 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration
Number of subjects: 110
Study 20594781 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (960 mg containing 2.4 mg S-allylcysteine) daily for 12 weeks
Number of subjects: 50
Study 20594781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20594781 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract
Number of subjects: 50
Study 17414091 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial infarction by postoperative day 4
Number of subjects: 2102
Study 16317370 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drops of 0.5% tropicamide
Number of subjects: 12
Study 16317370 — intervention group
Group type: COMPARATOR
Intervention: Single drop of unpreserved saline (Control)
Number of subjects: 12
Study 16317370 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drop of 0.5% tropicamide
Number of subjects: 12
Study 11955905 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz Hydroview H60M
Number of subjects: 73
Study 11955905 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal ACR6D
Number of subjects: 73
Study 11955905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioltech Stabibag
Number of subjects: 73
Study 11955905 — intervention group
Group type: COMPARATOR
Intervention: Stabibag
Number of subjects: 73
Study 11955905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroview and ACR6D
Number of subjects: 73
Study 9708721 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanate every 12 hours (875 mg amoxicillin; 125 mg clavulanate)
Number of subjects: 170
Study 9708721 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin and clavulanate every 8 hours (500 mg amoxicillin; 125 mg clavulanate)
Number of subjects: 170
Study 9708721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 170
Study 9566550 — intervention group
Group type: EXPERIMENTAL
Intervention: VaxSyn (recombinant HIV envelope subunit vaccine)
Number of subjects: 278
Study 9566550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum alone)
Number of subjects: 278
Study 1897329 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of salmon calcitonin daily as a nasal spray
Number of subjects: 20
Study 1897329 — intervention group
Group type: COMPARATOR
Intervention: Placebo as a nasal spray
Number of subjects: 20
Study 7043013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% malathion lotion (Prioderm lotion)
Number of subjects: 115
Study 7043013 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic vehicle of the lotion
Number of subjects: 115
Study 30541843 — intervention group
Group type: EXPERIMENTAL
Intervention: TbCSB iteron mutants
Number of subjects: 0
Study 30541843 — intervention group
Group type: COMPARATOR
Intervention: TbCSV
Number of subjects: 0
Study 30541843 — intervention group
Group type: EXPERIMENTAL
Intervention: SELEX assay
Number of subjects: 0
Study 30541843 — intervention group
Group type: EXPERIMENTAL
Intervention: Various betasatellite sequences
Number of subjects: 0
Study 29061871 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking 500 mL of water before vaccination
Number of subjects: 1807
Study 29061871 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1807
Study 23697602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg/day) plus paclitaxel (80 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Number of subjects: 0
Study 23697602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1000 mg/day) plus paclitaxel (70 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Number of subjects: 0
Study 23697602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (750 mg/day) plus paclitaxel (80 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Number of subjects: 0
Study 23697602 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts (combined)
Number of subjects: 0
Study 21294998 — intervention group
Group type: EXPERIMENTAL
Intervention: mirtazapine
Number of subjects: 65
Study 21294998 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 65
Study 21294998 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 65
Study 19699781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nav1.7 expression in patients with TN
Number of subjects: 0
Study 19699781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nav1.3 expression in patients with TN
Number of subjects: 0
Study 17353512 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion to elevate nocturnal blood pressure to mean daytime values
Number of subjects: 12
Study 17353512 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control condition)
Number of subjects: 12
Study 15333483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (5-7.5 mg/kg in divided doses)
Number of subjects: 56
Study 15333483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide
Number of subjects: 56
Study 15333483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 11530277 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 12
Study 11530277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9001476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad lib, low fat, high carbohydrate diet
Number of subjects: 43
Study 9001476 — intervention group
Group type: COMPARATOR
Intervention: Fixed energy intake diet
Number of subjects: 43
Study 8269785 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy combined with daily oral aspirin 100mg
Number of subjects: 60
Study 8269785 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 60
Study 3666663 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg diltiazem tablet (one tablet bid for 7 days)
Number of subjects: 12
Study 3666663 — intervention group
Group type: COMPARATOR
Intervention: 60 mg diltiazem tablet (two tablets bid for 7 days)
Number of subjects: 12
Study 31211930 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation threshold testing (DT+)
Number of subjects: 501
Study 31211930 — intervention group
Group type: COMPARATOR
Intervention: No defibrillation threshold testing (DT−)
Number of subjects: 501
Study 29101186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction <20 mm Hg
Number of subjects: 3090
Study 29101186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction between 20 and <40 mm Hg
Number of subjects: 3090
Study 29101186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction ≥40 mm Hg
Number of subjects: 3090
Study 29101186 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (target <140 mm Hg)
Number of subjects: 3090